Table 1 Criteria for inclusion and exclusion of patients.

1. Patients undergoing primary liver transplantation.

1. Pregnant or nursing women.

2. Patients older than 18 years.

2. Patients with a psychological, familial, sociologic or geographic condition potentially hampering compliance with the study protocol and follow-up schedule.

3. Patients with a hepatorenal syndrome.

3. Patients under guardianship, i. e., individuals who are not able to freely give their informed consent.

4. Female patients of childbearing potential willing to perform a highly effective contraception during the study and 12 weeks after conclusion of study participation. ^†

4. Patients with pre-transplant renal replacement therapy > 14 days.

5. eGFR < 50 ml/min at the time point of transplantation.

5. Patients with a reason for renal impairment other than a hepatorenal syndrome.

6. Serum creatinine levels > 1.5 mg/dL at the time-point of transplantation.

6. Patients with a known hypersensitivity to any of the investigational medicinal products.

7. Patients with thrombocytopenia (<50.000/nl), hypertriglyceridemia (> 350 mg/dl), or hypercholesterinemia (> 300 mg/dl), and patients with signs of hepatic artery stenosis prior to initiation of therapy with everolimus.